The climate emergency for rheumatologists: where do we stand?

被引:0
作者
Mruthyunjaya, Prakashini [1 ]
Sondur, Suhas [2 ]
Ahmed, Sakir [1 ]
Grainger, Rebecca [3 ]
机构
[1] KIIT Univ, Kalinga Inst Med Sci, Dept Clin Immunol & Rheumatol, Bhubaneswar, India
[2] KIIT Univ, Kalinga Inst Med Sci, Dept Orthopaed, Bhubaneswar, India
[3] Univ Otago, Dept Med, Wellington, New Zealand
关键词
Autoimmunity; Climate change; Epigenetics; Emerging infections; SYSTEMIC-LUPUS-ERYTHEMATOSUS; AIR-POLLUTION EXPOSURES; RHEUMATOID-ARTHRITIS; WEATHER CONDITIONS; ZIKA VIRUS; OXIDATIVE STRESS; CARBON FOOTPRINT; T-CELLS; OSTEOARTHRITIS; CHIKUNGUNYA;
D O I
10.1007/s10067-024-07284-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Climate change and pollution are a major existential threat. Healthcare contributes a noteworthy 4-6% to the total carbon footprint and 5-7% of the total greenhouse gas (GHG) emissions. Environmental pollution and modern lifestyles are also contributing to the increased prevalence of autoimmune and lifestyle-related rheumatic disease. In this review, we assess both the effects of rheumatological practice on climate change and the potential impact of climate change on rheumatological diseases. Preliminary evidence suggests that climate change is linked with the inception or exacerbation of some of the autoimmune and inflammatory rheumatic diseases (AIRDs) like rheumatoid arthritis, lupus, systemic sclerosis, and reactive arthritis. Furthermore, with rampant industrialization and pollution, emerging infections such as Dengue, Zika virus, and chikungunya have emerged as triggers of inflammatory arthritis. Strategies at different levels are proposed to mitigate the effect of the healthcare industry and the community on the environment. The rheumatology community can acknowledge and begin to address the challenges of climate change and health.
引用
收藏
页码:573 / 582
页数:10
相关论文
共 50 条
[41]   Immune-mediated processes in neurodegeneration: where do we stand? [J].
Marc Fakhoury .
Journal of Neurology, 2016, 263 :1683-1701
[42]   Current clinical trials for melanoma vaccines: where do we stand? [J].
Riker, Adam I. ;
Bisgaard, Erika .
MELANOMA MANAGEMENT, 2016, 3 (04) :255-257
[43]   Iron chelation therapy in myelodysplastic syndromes: where do we stand? [J].
Mitchell, Mhairi ;
Gore, Steven D. ;
Zeidan, Amer M. .
EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (04) :397-410
[44]   Ion Channels and Transporters in Immunity-Where do We Stand? [J].
Hoeger, Birgit ;
Zierler, Susanna .
FUNCTION, 2023, 4 (01)
[45]   Targeting T-cell memory: where do we stand? [J].
Valujskikh, Anna .
CURRENT OPINION IN ORGAN TRANSPLANTATION, 2008, 13 (04) :344-349
[46]   Arthroscopic partial meniscectomy for degenerative tears: where do we stand? [J].
Katz, J. N. ;
Losina, E. .
OSTEOARTHRITIS AND CARTILAGE, 2014, 22 (11) :1749-1751
[47]   Sex Differences in Alzheimer's Disease: Where Do We Stand? [J].
Medeiros, Andre de Macedo ;
Silva, Regina Helena .
JOURNAL OF ALZHEIMERS DISEASE, 2019, 67 (01) :35-60
[48]   Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go? [J].
Nemeth, Tamas ;
Nagy, Gyorgy ;
Pap, Thomas .
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (08) :1055-1064
[49]   Where do we stand on the 17 Sustainable Development Goals? An overview on progress [J].
Halkos, George ;
Gkampoura, Eleni-Christina .
ECONOMIC ANALYSIS AND POLICY, 2021, 70 :94-122
[50]   Haematopoietic stem cell transplantation for SCID patients: where do we stand? [J].
Cavazzana-Calvo, Marina ;
Andre-Schmutz, Isabelle ;
Fischer, Alain .
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (02) :146-152